Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Para-toluenesulfonamide - Gongwing Biopharma

Drug Profile

Para-toluenesulfonamide - Gongwing Biopharma

Alternative Names: 4-toluenesulfonamide; P-toluenesulfonamide - PTS International; PTS-02; PTS-100; PTS-302; PTS-500

Latest Information Update: 30 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Vision Drugs Development; PTS International
  • Developer Beijing Vision Drugs Development; Gongwin Biopharm
  • Class Antineoplastics; Small molecules; Sulfonamides; Toluenes
  • Mechanism of Action Cell death stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adenoid cystic carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Lung cancer
  • Phase II Liver cancer; Solid tumours
  • Phase I Adenoid cystic carcinoma; Malignant pleural effusion
  • Discontinued Breast cancer

Most Recent Events

  • 30 Aug 2023 Phase II development is still ongoing for Liver cancer (Inoperable/Unresectable) in Taiwan (Intratumoural) (Gongwin Biopharm pipeline, August 2023) (NCT03447951)
  • 29 Aug 2023 Phase-I clinical trials in Adenoid cystic carcinoma in China (Intratumoural) prior to August 2023 (Gongwin Biopharm pipeline, August 2023)
  • 29 Aug 2023 Phase-I clinical trials in Malignant pleural effusion in China (Intratumoural) (Gongwin Biopharm pipeline, August 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top